SALIX PHARMACEUTICALS LTD Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2014-12-31..
Quick ratio
Overview →Financial period ending 2014-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2014-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.48B USD | Liabilities, Current |
| Cash and equivalents | 499.34M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 42.52M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 175.16M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2014-12-31 | (m) | $1.48B | $499.34M | (m) | $42.52M | $175.16M | (m) |
| 2014-09-30 | (m) | $1.60B | $422.58M | (m) | $507.43M | $151.09M | (m) |
| 2014-06-30 | (m) | $941.30M | $435.26M | (m) | $481.49M | $142.84M | (m) |
| 2014-03-31 | (m) | $582.43M | $385.10M | (m) | $437.56M | $145.78M | (m) |
| 2013-12-31 | (m) | $417.24M | $1.16B | (m) | $133.58M | $104.21M | (m) |
| 2013-09-30 | (m) | $331.82M | (m) | (m) | $389.75M | $106.28M | (m) |
| 2013-06-30 | (m) | $277.46M | (m) | (m) | $282.77M | $105.01M | (m) |
| 2013-03-31 | (m) | $281.76M | (m) | (m) | $111.52M | $108.73M | (m) |
| 2012-12-31 | (m) | $260.92M | $751.01M | (m) | $268.24M | $90.53M | (m) |
| 2012-09-30 | (m) | $233.40M | (m) | (m) | $213.77M | $71.65M | (m) |
| 2012-06-30 | (m) | $228.23M | (m) | (m) | $211.68M | $63.64M | (m) |
| 2012-03-31 | (m) | $209.15M | (m) | (m) | $193.20M | $56.82M | (m) |
| 2011-12-31 | (m) | $210.65M | (m) | (m) | $151.21M | $49.20M | (m) |
| 2011-09-30 | (m) | $166.50M | (m) | (m) | $169.91M | $44.21M | (m) |
| 2011-06-30 | (m) | $140.37M | (m) | (m) | $152.09M | $34.07M | (m) |
| 2011-03-31 | (m) | $146.82M | (m) | (m) | $101.48M | $27.21M | (m) |
| 2010-12-31 | (m) | $125.17M | (m) | (m) | $140.18M | $16.02M | (m) |
| 2010-09-30 | (m) | (m) | $491.47M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $461.25M | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $198.04M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $192.51M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $120.15M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.